Unknown PHASE2/PHASE3 INTERVENTIONAL 2-arm NCT00545493

Efficacy of Tacrolimus and I.V.-Immunoglobulins in Rasmussen Encephalitis

Efficacy of Tacrolimus and i.v.-Immunoglobulins in Rasmussen Encephalitis With Start of Treatment in the Acute Disease Stage. Prospective, Randomised, Open Parallel Group Study

Sponsor: Astellas Pharma GmbH

Conditions Rasmussen Encephalitis

Interventions Tacrolimus i.v. immunoglobulins

Updated 5 times since 2017 Last updated: Apr 9, 2009 Started: Nov 30, 2002 Primary completion: Apr 30, 2010 Completion: Apr 30, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2/PHASE3 trial investigates Rasmussen Encephalitis and is currently ongoing. Astellas Pharma GmbH leads this study, which shows 5 recorded versions since 2002 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE2/PHASE3
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE2/PHASE3

Status: Unknown Status → Unknown · Phase: PHASE2_PHASE3 → PHASE2/PHASE3
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE2_PHASE3
Jun 2018 — Jan 2021 [monthly]

Unknown Status PHASE2_PHASE3
Jan 2017 — Jun 2018 [monthly]

Unknown Status PHASE2_PHASE3

First recorded

Nov 2002

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Astellas Pharma GmbH
Octapharma
University Hospital, Bonn

Data source: University Hospital, Bonn

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Bonn, Germany